You can find out more about NPF's National Medical Director, Dr. Michael S. Okun, by also visiting the NPF Center of Excellence, University of Florida Center for Movement Disorders & Neurorestoration.
Note: You can also watch Dr. Okun address this topic in a video appearing at the end of this blog entry.
Hailed as a major breakthrough for Parkinson’s disease research, investigators from multiple institutions throughout the United States published an important paper on gene therapy in March 2011. The study was a double-blind (neither the investigators nor the patients knew which patients were receiving the real treatment) randomized trial, and was one of the largest of its type to be performed in actual Parkinson’s disease patients. The study utilized a clever and novel technology in order to change the nature of a nucleus in the brain called the subthalamic nucleus, which in PD becomes overactive leading to the movement disorders characteristic of the condition. The nucleus normally infuses excitatory chemicals into the brain, but was converted to infuse inhibitory chemicals. The investigators accomplished their goal by utilizing gene transfer of glutamic acid acid decarboxylase, or GAD into the subthalamic nucleus region. This technique was performed on two sides of each participant’s brain, and some patients received a sham surgery (a mock procedure designed to mimic the experimental approach). Although the results were not as robust as what has been observed with deep brain stimulation and with other therapies, the door seems to have swung open for gene therapy approaches in Parkinson’s disease.
The study included patients between the ages of 30 and 75 years who had a diagnosis of Parkinson's disease, and a very good response to levodopa therapy. Seven centers participated from across the United States. The study used a novel technology to apply gene therapy at the bedside, rather than in an operating room setting. Motor scores on a scale called the UPDRS were used as the primary outcome. Sixty-six patients were included in the study, and 23 were assigned to receive sham surgery and 22 assigned to gene therapy infusion. What is interesting about this study was that the investigators designed a completely sham procedure in order to be sure that there was a difference between the gene therapy group, and the sham operated group. The motor scores improved by eight points in the gene therapy group, and by nearly 5 points in the sham group. This was a significant difference favoring the gene therapy group. Only 21 sham surgery patients and 16 gene therapy patients of the original 66 were analyzed for primary outcomes meaning that the study was smaller than one may have hoped for. Importantly, the adverse event and safety profile were reported as excellent, with the most common side effect being headache (seven patients in the gene therapy group and only two in the sham group complained of this symptom). The study authors felt that this therapy should be further explored for Parkinson’s disease.
Though the results of this study were positive, patients should not come away with false impressions and with false hopes. This type of gene therapy was targeted as a symptomatic approach to address levodopa responsive Parkinson's disease issues. It was not a neuroprotective approach, nor was it a disease modifying approach. The benefits were mainly mild improvements in the motor symptom scale. Though the therapy fared better than sham, it did not perform better than deep brain stimulation performed in the same target (as reported by other recent studies).
The future of gene therapy for Parkinson's disease we hope will be bright. The lessons from early studies such as the one published in Lancet Neurology should point us in the right direction. Larger numbers of patients will need to be examined, outcomes optimized, and safety documented. There is an overriding concern for the future of gene therapy in long-term delayed adverse events, and we will need to carefully document their presence or absence. The transplant trials in Parkinson’s disease patients taught us important lessons including the appearance of delayed complications, one of which runaway dyskinesia, proved to be a limiting issue for continuation of the therapy.
Hopefully gene therapy approaches can be modified to address non-medication responsive symptoms of Parkinson's disease. Remember, this current gene therapy approach was aimed at achieving symptomatic improvement of levodopa responsive Parkinson's disease symptoms. The field remains however, in desperate need of therapies targeting both motor and non-motor symptoms that are resistant to levodopa and other therapies. These symptoms include but are not limited to walking, balance, speech, swallowing, cognition, mood, and sexual dysfunction.
We remain very encouraged about gene therapy and its possibilities for future use in Parkinson’s disease patients. This study will hopefully help to open some doors and to challenge our scientists to continue to develop and to continue to refine techniques that will target the symptoms that matter the most to our patients with Parkinson disease, mainly the levodopa resistant symptoms.
Lewitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind,sham-surgery controlled, randomised trial. Lancet Neurol. 2011 Mar 16. [Epub ahead of print] PubMed PMID: 21419704.
Posted: 4/1/2011 6:03:37 AM by
Browse current and archived What's Hot in PD? articles, the National Parkinson Foundation's monthly blog for people with Parkinson's written by our National Medical Director, Dr. Michael S. Okun.
Is Midlife Migraine Related to Late Life Parkinson’s Disease?
Deep Brain Stimulation for Parkinson’s Disease: NPF Congratulates Mahlon DeLong and Alim-Louis Benabid and Looks to a Bright Future in Human Neural-Network Modulation
Everything You Need to Know About Medical Marijuana and Parkinson’s Disease
The End for Levodopa Phobia: New Study Shows Sinemet is a Safe Initial Therapy for Treatment of Parkinson's Disease
Is light therapy a potential treatment modality in Parkinson’s disease?
How does the most common genetic cause of Parkinson’s Disease (LRRK2) cause Parkinson’s disease and could it be used to help develop a better therapy?
An Update on DAT Scanning for Parkinson’s Disease Diagnosis
Could Northera (Droxidopa) Be an Alternative Treatment for Low Blood Pressure and Passing Out Symptoms?
The Dream of a Pill Free Existence and the Continuous Dopaminergic Pump for the Treatment of Parkinson's Disease
Should I take Inosine to Raise my Uric Acid Levels and Treat my Parkinson’s Disease?
Could Fungus and Mold be an Important Contributor to Parkinson’s Disease?
Pimavanserin and the Hope for a Better Drug for Hallucinations and Psychosis in Parkinson’s Disease
Halting of the Creatine Study
The Importance of Identifying and Treating Caregiver Strain
Putting Parkinson’s Disease Information into the Palm of Your Hand: Parkinson’s Enters the Smartphon
What Parkinson’s Disease Patients Need to Know about H. Pylori Gastrointestinal Infections
A2A Receptor Antagonists and Parkinson’s Disease Treatment
Another Setback for Trophic Factor Treatment in Parkinson's Disease
IPX066 and What Patients Really Want in New Carbidopa/Levodopa (Sinemet) Formulations
The Weather Forecast for Parkinson’s Disease Calls for Worldwide Economic Storm
Defeating the Barriers to Implementing Exercise Regimens in Parkinson’s Disease Patients
When should you start medication therapy for Parkinson’s disease?
Neurologist Care Reduces Hospitalizations in Parkinson's Disease
A Victory in Court for Parkinson's Disease Patients who Require Ongoing Rehabilitative Therapies
Given the recent FDA announcement about Mirapex (pramipexole), should I be worried about dopamine agonists?
What about the new Parkinson’s Disease Vaccine? What should I know?
Caffeine as a Potential Treatment for Parkinson’s Disease
Time to Consider GPi DBS for Parkinson’s Disease: A Shift in the Practice of Patient Selection for DBS
A New Treatment for Parkinson’s Disease-Related Constipation
Too Many Pills: Improving Delivery Systems for Parkinson’s Disease Drugs
Measuring Quality and Assessing Depression in Parkinson's Disease
Watch out for Unexpected Obstacles if You Use a Cueing Strategy to Break Freezing of Gait in Parkinson’s Disease
Pill Color, Generic Medications and Insurance Issues: Important Medication-Related Tips for the Parkinson’s Disease Patient
Are Blood Tests for Parkinson’s Disease on the Horizon?
Placing Stem Cells in Animal Models of Parkinson’s Disease: Another Important Step
Important News for the Parkinson’s Disease Community: More Evidence that Sinemet and Madopar are Not Toxic and do Not Accelerate Disease Progression
The Case for All Parkinson’s Disease Patients to be Co-managed by a Primary Care-Neurologist Team
Scientists say Research on Brain Proteins Involved in Parkinson’s Disease is “Shaping” Up
Who Actually Takes Care of Most of the Parkinson’s Patients Worldwide: The Need for Education and the Parkinson’s Toolkit
If you are Dizzy or Passing Out, it could be Your Parkinson’s Disease or Parkinson’s Disease Medications
How Will Group Visits for Parkinson’s Disease Fit into the Future of Parkinson’s Disease Care?
Why Patients Should be Wary of Chelation Therapy for Parkinson’s Disease
Opening the Door to Gene Therapy in Parkinson’s Disease: The Need for Refinement of the Technology and Approach
Does it Matter if I Can’t Get Brand Sinemet?
Should I get a DaTscan or PET scan to confirm my diagnosis of Parkinson’s disease?
A Critical Reappraisal of the Worst Drugs in Parkinson’s Disease
Environmental Risks for PD: Manganese, Welding, Mining, and Parkinsonism
Calling for the FDA to Revise the Eight Sinemet a Day Rule
Dry Cleaning Solvents and Potential Environmental Risks for Developing Parkinson’s Disease
Maintaining the Balance: Why Parkinson’s Disease Patients Need to Understand Drug Recalls, Withdrawals, and Safety Alerts
Shining a Light on Parkinson’s Disease: Optogenetics Has a Bright Future in Research
Poor Medication Management of Parkinson's Disease During Hospital Admissions: Patients and Families Can Improve Their Hospital-Based Management
Why Are Patches and Continuous Release Technology a Big Deal to Parkinson's?
Is the PD SURG Trial Another Surge Forward for DBS Therapy?
Cycling in PD in Those Who Can’t Walk: Is it Possible?
New iPS Stem Cells for PD: What Does it Mean?
Time for Comprehensive Care Networks for PD
Is Parkinson's Disease a Prion Disease?
Parkinson's Disease Linked to Gaucher's Disease
Brain Cells Keep Time Stamps: Implications for Parkinson's Disease Therapies
Is it Safe to Have an MRI with a DBS in Place?
Take Care of Your Bones as They Are Affected in Parkinson's Disease (Even in Men)
Is it Time to Start Paying Attention to Pain Symptoms in Parkinson's Disease Patients?
Glutathione Fails to Demonstrate Significant Improvement in PD Symptoms
Keeping an Eye on Trials Important to the Parkinson's Disease Patient
Increased Risk of Melanoma in Parkinson's Disease
Finally a DBS Expert Consensus Statement Aimed at Their True Customers: The Patients
Pesticides and Environmental Exposure in Parkinson's disease: Should We Stay Away From the Stink Truck?
Is Exercise Effective Treatment and Protection Against PD?
Why are Transplant Trials Struggling to Succeed in the Treatment of PD?
Are Monoamine Oxidase Inhibitors Disease Modifying or Neuroprotective in PD?
Update on Gene Therapy for Parkinson's Disease